Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
276.25
+1.54 (0.56%)
Sep 18, 2025, 10:37 AM EDT - Market open
Amgen Revenue
Amgen had revenue of $9.18B in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.92B, up 12.88% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.92B
Revenue Growth
+12.88%
P/S Ratio
4.23
Revenue / Employee
$1,247,036
Employees
28,000
Market Cap
148.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AMGN News
- 4 days ago - Amgen: Buy The Dip Opportunity - Seeking Alpha
- 7 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 8 days ago - US FDA to step up enforcement of pharma ads, sends enforcement letters - Reuters
- 8 days ago - Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 9 days ago - Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis - GlobeNewsWire
- 9 days ago - AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS - PRNewsWire
- 12 days ago - September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog - Seeking Alpha
- 13 days ago - AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE - PRNewsWire